dApagliflozin SC0062 and Prevention of Renal Injury; a Randomized Evaluation

Inclusion Criteria: * Willing and able to sign informed consent * Male or female individuals diagnosed with type 1 diabetes at least 6 months prior to informed consent * WOCBP must have a negative pregnancy test at screening and must not be lactating. * Male individuals must use highly effective method of contraception for the duration of the study (from the time they sign consent) and for 4 weeks after the last dose of study medication, or be able to provide proof of vasectomy. * Female individuals must use highly effective method of contraception for the duration of the study (from the time they sign consent) and for 4 weeks after the last dose of study medication, provide proof of hysterectomy or sterilization, or be deemed menopausal based on a FSH-test. * Age ≥18 and \<65years, at the time of signing consent. * Body Mass Index ≥ 21 kg/m2 * Urinary albumin:creatinine ratio ≥ 50 mg/g and \<3000 mg/g * eGFR ≥30 and \<90 ml/min/1.73m2 * Stable RAAS inhibition medication for at least 4 weeks prior to screening * HbA1c ≥6.5 and \<10.5%. * Based on the Investigator's judgment participant must have a good understanding of his/her disease and how to manage it, and be willing and capable of performing the following study assessments (assessed before randomization): * patient-led management and adjustment of insulin therapy * reliable approach to insulin dose adjustment for meals, such as carbohydrate counting * reliable and regular home-based blood glucose monitoring * e…